News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Bard1 caps off 600pc+ in 6 weeks proving it can detect another type of cancer
Health & Biotech
Exopharm preps for great LEAP forward as world catches onto exosome promise
News
Trading Places: Bevan Slattery’s $2m buy into Rent.com.au is now worth over $10m just one week later
Experts
Value in new medicines and ‘longer strides’
News
Last Orders: What you might have missed on the ASX today
Experts
MoneyTalks: A few more hot picks out of COVID from Canary Capital
Health & Biotech
Exopharm’s LEAP technology a breakthrough in exosome therapeutics
Health & Biotech
Exopharm has just dosed it first patient in a wound-healing study
Health & Biotech
Health Kick Podcast: This biopharma company may be the world’s only exosome-based player
Health & Biotech
How mRNA vaccines could defeat the novel coronavirus
Health & Biotech
Check up: Health sector slips as earning season ends
News
ASX Small Cap Lunch Wrap: ‘Only in America’ edition
Health & Biotech
Canary Capital sees explosive potential in Exopharm
Health & Biotech
Nanoveu says there are other ways to clean your phone from corona, shares fly
Health & Biotech
Are we mortgaging the future as COVID-19 closes clinical trials?
Health & Biotech
